KLK3 and prostate cancer: Besides, it is reported oral administration of curcumin for 6 months (1440 mg/day) did not significantly affect the overall cessation time of intermittent androgen deprivation in prostate cancer patients, but the intake of curcumin significantly inhibited the elevation of prostate-specific antigen (PSA) during this period, indicated curcumin has potential beneficial effects on prostate cancer patients.667 Although this study failed to demonstrate the difference of the off-treatment duration in the curcumin group, it is the first clinical study to use curcumin alone on prostate cancer.